Does Vyvanse cause hair loss? Hair loss is not listed as a standard side effect in Vyvanse’s official prescribing information, and there is no established causal link proven in large-scale clinical trials. However, peer-reviewed case reports, patient pharmacovigilance data, and the broader literature on amphetamine-class medications make clear that hair loss can and does occur in a subset of Vyvanse users. The most likely causes are indirect — nutritional deficiency from appetite suppression, physiological stress on the hair cycle, and telogen effluvium from the body’s response to a significant neurological change — rather than a direct pharmacological action on hair follicles.
What the Clinical Evidence Actually Shows
The evidence base for Vyvanse and hair loss is small but meaningful, and importantly it is not purely anecdotal:
The first reported case — published in PMC (peer-reviewed):A 2009 case report published in Annals of Pharmacotherapy documented the first recorded case of diffuse hair thinning secondary to lisdexamfetamine use in a paediatric patient. The hair loss began just five days after starting lisdexamfetamine, stopped within two days of discontinuation, and did not recur when the patient was switched to a different formulation. Applying the Naranjo Adverse Drug Reaction Probability Scale — the standard pharmacological tool for assessing whether a drug caused an adverse event — yielded a score of 7, classified as a probable medication-related event. The paper notes that alopecia secondary to amphetamine use was first reported as far back as the 1960s when amphetamines were used for weight loss, with the mechanism not fully identified in any study to date.
Additional clinical reports:A 2025 review in a UK clinical journal identified multiple published case studies associating stimulant medications — including lisdexamfetamine specifically — with diffuse or patchy hair loss in children and adolescents, some of which resolved upon discontinuation or dose stabilisation. The same review identified a specific association with Vitamin D deficiency as an exacerbating factor in some cases.
The honest summary of the evidence:Hair loss from Vyvanse is rare, not officially listed as a standard adverse effect, and insufficiently studied in large trials to establish prevalence. But the case evidence is sufficient to conclude it can occur as a probable medication effect in some users — and that the clinical authors who first documented it explicitly encouraged prescribers to be aware of the possibility.
Why Hair Loss from Vyvanse Is Not Simply “Direct Pharmacological Action”
Understanding why Vyvanse might cause hair loss requires understanding the normal hair growth cycle — because the most likely mechanisms work by disrupting this cycle rather than by directly damaging follicles:
The normal hair growth cycle has three phases:
- Anagen (growth phase): Lasting 2–7 years; hair is actively growing
- Catagen (transition phase): 2–3 weeks; hair follicle shrinks and detaches from blood supply
- Telogen (resting/shedding phase): 3 months; the hair rests then falls out naturally
Hair loss becomes visible when an abnormal proportion of follicles shift prematurely from the anagen to the telogen phase — a pattern called telogen effluvium. This is the most likely mechanism by which Vyvanse — and stimulants broadly — can produce diffuse hair shedding rather than isolated bald patches.
The Most Probable Mechanisms
Nutritional Deficiency From Appetite Suppression
This is the most widely cited and most clinically plausible mechanism:
Vyvanse significantly suppresses appetite — it is one of the most common and consistent side effects, present in the majority of patients. When appetite suppression is pronounced and patients regularly skip meals or eat insufficiently, the result is nutritional depletion across multiple micronutrients critical to hair follicle health:
- Iron deficiency — one of the most established causes of telogen effluvium; depleted iron impairs the mitochondrial activity that drives rapid cell division in hair follicles
- Zinc deficiency — zinc plays a direct role in the anagen-to-telogen transition; deficiency accelerates shedding
- Biotin (Vitamin B7) deficiency — biotin deficiency is classically associated with hair thinning and loss
- Protein deficiency — hair is approximately 95% keratin, a protein; inadequate dietary protein directly limits the structural substrate for hair growth
- Vitamin D deficiency — the clinical literature specifically identifies vitamin D deficiency as an exacerbating factor in stimulant-associated hair loss
The pattern of hair loss from nutritional deficiency is diffuse — general thinning across the scalp rather than localised bald patches — which matches the presentation reported in most Vyvanse-related hair loss cases.
Physiological Stress Response
Vyvanse elevates cortisol — the body’s primary stress hormone — as part of its adrenergic activation mechanism. Sustained elevated cortisol is a well-established cause of telogen effluvium: it signals to hair follicles that the body is under threat, causing a premature shift from the growth to the resting phase as a resource-conservation mechanism.
For patients who experience significant anxiety, sleep disruption, or cardiovascular strain on Vyvanse — particularly in the first weeks — this stress-mediated hair cycle disruption is a plausible independent contributor to shedding.
Direct Effect on the Hair Growth Cycle
The mechanism that is least understood but most pharmacologically specific — the possibility that dextroamphetamine, through its effects on the catecholamine system, directly alters the signalling that regulates the hair growth cycle. The 1960s reports of amphetamine-associated hair loss, noted in the original 2009 lisdexamfetamine case report, suggest this may be a class effect of amphetamines that predates their use as ADHD medications. The mechanism has never been definitively characterised in subsequent research.
Hormonal Disruption
Stimulants can influence sex hormone levels, particularly testosterone metabolism in some patients. Elevated dihydrotestosterone (DHT) — a testosterone metabolite — is the primary driver of androgenetic alopecia (pattern hair loss). Whether Vyvanse produces DHT-level changes sufficient to accelerate androgenetic alopecia has not been formally studied, but it is a plausible mechanism in genetically predisposed individuals.
Who Is Most Likely to Experience Hair Loss on Vyvanse
Not all Vyvanse users experience hair loss — these factors increase the risk:
- Significant, sustained appetite suppression — patients who are regularly undereating due to stimulant-related anorexia are most nutritionally vulnerable
- Pre-existing nutritional deficiencies — iron deficiency anaemia, vitamin D deficiency, and zinc insufficiency are more common in women of reproductive age, vegetarians, and people with restrictive eating patterns
- High doses — more pronounced appetite suppression and greater physiological stress activation
- Female patients — women are generally more susceptible to telogen effluvium from nutritional and hormonal triggers; additionally, post-partum hormonal shifts and perimenopause may compound Vyvanse-related hair cycle disruption
- Patients with a personal or family history of androgenetic alopecia — the genetic predisposition may interact with any hormonal or stress-related changes
- High baseline stress or anxiety — the cortisol elevation from Vyvanse compounds existing stress-driven hair loss
- Recent significant weight loss — whether from Vyvanse’s appetite suppression or other causes, rapid weight loss is an independent trigger of telogen effluvium
What the Hair Loss Looks Like: Type and Pattern
Vyvanse-related hair loss, when it occurs, follows a characteristic diffuse pattern:
- Diffuse thinning across the entire scalp — not localised bald patches
- Increased shedding — noticeable excess hair on the pillow, in the shower, or when brushing
- General reduction in hair volume and density rather than visible bare areas
- Onset typically weeks to months after starting Vyvanse — reflecting the 3-month telogen phase before shed hairs become visible; the trigger may have occurred well before the loss is apparent
This diffuse pattern is characteristic of telogen effluvium and is distinct from:
- Alopecia areata — circular, defined bald patches
- Androgenetic alopecia — gendered pattern hair loss concentrated at the crown or temples
- Traction alopecia — hair loss at the hairline from physical tension
The diffuse pattern of Vyvanse-related loss is clinically important because it is among the most reversible types — telogen effluvium typically resolves when the trigger is removed, and the follicles are not permanently damaged.
Does Vyvanse-Related Hair Loss Grow Back?
For most patients, yes — with important qualifications:
- If the cause is nutritional deficiency: Hair regrowth begins once nutritional status is restored; full regrowth typically takes 3–6 months after nutrient levels normalise
- If the cause is telogen effluvium from physiological stress: Most cases resolve within 6–12 months of the trigger being removed or reducing
- If Vyvanse is discontinued: The hair loss reported in the original case study stopped within two days of stopping the medication and did not recur on a different formulation. Full regrowth takes longer — typically 3–6 months — as new anagen growth replaces shed telogen hairs
- For men with genetic predisposition to androgenetic alopecia: Hair loss from the receding hairline zone may not fully reverse, as this hair may have been in a late androgenetic phase regardless of the medication
The key clinical message: in most patients who experience hair loss on Vyvanse, the follicles are not permanently damaged and regrowth is the expected outcome with appropriate management.
What to Do If You’re Experiencing Hair Loss on Vyvanse
Step 1: Assess Your Nutrition Honestly
Before attributing hair loss to Vyvanse itself, evaluate your nutritional intake:
- Are you regularly skipping meals due to appetite suppression?
- Have you lost significant weight since starting Vyvanse?
- Is your diet adequate in iron, protein, zinc, and vitamin D?
A full blood count, iron studies, ferritin, zinc, and vitamin D blood test is the appropriate first investigation — ask your GP to run these alongside any prescriber review.
Step 2: Address Nutritional Gaps Actively
If nutritional deficiency is identified or suspected:
- Make eating a structured, timed activity rather than appetite-driven — set meal alarms and eat whether you feel hungry or not
- Prioritise iron-rich foods — red meat, legumes, leafy greens — combined with vitamin C to enhance absorption
- Consider supplementing: ferrous sulfate if iron deficient (prescriber guidance); zinc (8–11 mg/day); biotin (2.5 mg/day — widely available OTC); vitamin D (1,000–2,000 IU/day if deficient)
- Ensure adequate daily protein — at least 0.8–1.2 g per kg of body weight
Step 3: Discuss With Your Prescriber
Report the hair loss specifically and ask your prescriber to consider:
- Whether a dose reduction may reduce the nutritional and stress-mediated hair loss triggers
- Whether the hair loss began within weeks of starting Vyvanse or a dose increase — this temporal connection is the most important indicator of medication causality
- Whether a different ADHD medication may be worth trialling if hair loss is significant and persistent
Step 4: Manage Stress-Related Components
If anxiety and sleep disruption are also present alongside the hair loss:
- Addressing sleep quality (see dosing timing strategies) reduces cortisol elevation that drives stress-related telogen effluvium
- CBT and mindfulness practice reduce cortisol levels independently of medication changes
- Reducing caffeine decreases adrenergic activation and its associated cortisol contribution
Step 5: Be Patient With Regrowth
If you have identified and addressed the cause, set realistic expectations for regrowth:
- Shedding typically continues for 1–3 months after the trigger is removed, because the hairs already in the telogen phase must complete their cycle before new growth replaces them
- Visible new growth typically becomes apparent at 3–4 months
- Full recovery of density can take 6–12 months
Safety and Important Considerations for Australian Adults
- Hair loss from Vyvanse is not listed in the Australian TGA Consumer Medicine Information as a standard adverse effect — but this does not mean it cannot occur; it means it was not reported at sufficient frequency in pre-approval clinical trials to meet the threshold for inclusion
- The TGA’s Adverse Drug Reactions (ADR) reporting system (reports.tga.gov.au) allows patients to directly report suspected adverse effects including hair loss — your report contributes to post-market safety surveillance of all medicines including Vyvanse
- Women of reproductive age are disproportionately represented in reports of Vyvanse-related hair loss and are more vulnerable to nutritional-deficiency-triggered telogen effluvium — particular attention to iron and ferritin is warranted in this group
- Do not stop Vyvanse abruptly due to hair loss concerns without prescriber guidance — the reintroduction and management options available (dose adjustment, nutritional support) are worth exploring before discontinuation
Common Misconceptions About Vyvanse and Hair Loss
Myth 1: “Hair loss isn’t a real Vyvanse side effect — it’s not in the prescribing information.”Absence from the official prescribing information reflects the threshold for inclusion in clinical trial adverse event listings — it does not mean the effect does not exist. Peer-reviewed case reports published in pharmacology journals, a Naranjo score of 7 (probable drug reaction) in the first published case, and decades of reports linking amphetamine-class medications to diffuse hair loss collectively constitute sufficient evidence to take this seriously.
Myth 2: “The hair loss is permanent.”For the overwhelming majority of patients experiencing Vyvanse-related diffuse hair loss, the follicles are not permanently damaged and regrowth is the expected outcome. Telogen effluvium is by nature a reversible process — the trigger shifts follicles into the resting phase, but when the trigger is removed, they re-enter the growth phase. The exception is patients with genetic androgenetic alopecia in areas of the scalp already in late-stage follicle miniaturisation.
Myth 3: “Taking biotin will fix Vyvanse hair loss.”Biotin supplementation helps specifically when biotin deficiency is the cause — and this is only one of several possible mechanisms. If the cause is iron deficiency, cortisol elevation, or direct pharmacological disruption of the hair cycle, biotin will not be sufficient. A targeted approach based on identifying the actual mechanism is more effective than a single supplement.
Myth 4: “If Vyvanse is causing hair loss, I have to stop taking it.”Not necessarily — the management options include nutritional optimisation, dose reduction, and switching formulation, all of which have been associated with resolution of hair loss without requiring complete discontinuation of ADHD treatment. Discontinuation is one option, not the only one, and the clinical conversation with your prescriber should explore all approaches before this step.
Does Vyvanse cause hair loss Hobart
Does Vyvanse cause hair loss Devonport
Does Vyvanse cause hair loss Launceston
Does Vyvanse cause hair loss Tasmania
Does Vyvanse cause hair loss Victoria
Does Vyvanse cause hair loss Queensland
Does Vyvanse cause hair loss Canberra
Does Vyvanse cause hair loss Australian Capital Territory
Does Vyvanse cause hair loss South Australia
Does Vyvanse cause hair loss New South Wales
Does Vyvanse cause hair loss Darwin
Does Vyvanse cause hair loss Ghan
Does Vyvanse cause hair loss Northern Territory
Does Vyvanse cause hair loss Australia
Does Vyvanse cause hair loss Austria
Does Vyvanse cause hair loss Germany
Does Vyvanse cause hair loss United Kingdom
Does Vyvanse cause hair loss Sweden
Does Vyvanse cause hair loss Denmark
Does Vyvanse cause hair loss Norway
Does Vyvanse cause hair loss Finland
Does Vyvanse cause hair loss Iceland
Does Vyvanse cause hair loss Netherlands
Does Vyvanse cause hair loss Spain
Does Vyvanse cause hair loss Ireland
Does Vyvanse cause hair loss Switzerland
FAQ: People Also Ask About Vyvanse and Hair Loss
Does Vyvanse cause hair loss in women?Women are disproportionately affected by Vyvanse-related hair loss for two reasons: they are more biologically susceptible to nutritional-deficiency-triggered telogen effluvium (particularly iron deficiency, which is common in women of reproductive age), and hormonal factors such as menstrual cycle, post-partum changes, and perimenopause can interact with stimulant-related stress responses to compound hair loss risk. Hair loss from Vyvanse in women is typically diffuse thinning rather than patterned loss, and is reversible with appropriate management in the majority of cases.
How long does Vyvanse hair loss last?If the cause is nutritional deficiency, shedding typically reduces within 1–3 months of nutritional restoration, with visible regrowth at 3–4 months and full density recovery over 6–12 months. If Vyvanse is discontinued as the primary intervention, shedding stopped within days in the published case report, with regrowth following over subsequent months. The timeline is highly individual and depends on how long the trigger was active before it was identified and addressed.
Is Vyvanse hair loss reversible?Yes — for most patients, and in most cases. Vyvanse-related hair loss follows the diffuse telogen effluvium pattern, in which follicles are temporarily shifted to the resting phase but retain their growth capacity. Follicle damage is not the mechanism, and regrowth is expected once the trigger is removed or managed.
Can reducing my Vyvanse dose reduce hair loss?Possibly — if the hair loss is driven by appetite suppression leading to nutritional depletion, reducing the dose reduces appetite suppression and allows improved nutritional intake. If the hair loss is driven by cortisol elevation from stimulant-induced physiological stress, a lower dose reduces that stress activation. A dose reduction is a reasonable option to discuss with your prescriber if hair loss is significant and confirmed to be medication-related.
What nutritional supplements help with Vyvanse hair loss?The most evidence-supported nutritional interventions for stimulant-related hair loss are: iron/ferritin (investigate first with blood tests — supplement only if deficient; excess iron is harmful), zinc (8–11 mg/day), biotin (2.5 mg/day), vitamin D (1,000–2,000 IU/day if deficient), and adequate dietary protein (0.8–1.2 g/kg body weight daily). A targeted approach based on blood test results is more effective than blanket supplementation.
Should I tell my doctor about hair loss from Vyvanse?Yes — always. Your prescriber needs to know about all side effects you’re experiencing, including those not listed in the standard prescribing information. Hair loss may indicate significant nutritional deficiency that requires investigation and treatment beyond simply managing the hair loss itself. It also informs the risk-benefit assessment of continuing at the current dose and may warrant blood tests to identify modifiable contributing factors.
